Lexicon Pharmaceuticals (LXRX) to Release Quarterly Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) will issue its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The firm had revenue of $1.13 million for the quarter, compared to the consensus estimate of $1.17 million. Lexicon Pharmaceuticals had a negative net margin of 8,311.12% and a negative return on equity of 108.54%. On average, analysts expect Lexicon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX stock opened at $2.27 on Wednesday. Lexicon Pharmaceuticals has a one year low of $0.92 and a one year high of $3.73. The company’s fifty day moving average price is $1.85 and its 200-day moving average price is $2.00. The company has a debt-to-equity ratio of 0.35, a quick ratio of 15.56 and a current ratio of 15.58.

Analyst Ratings Changes

LXRX has been the topic of several recent analyst reports. Leerink Partnrs restated an “outperform” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, April 30th. StockNews.com raised shares of Lexicon Pharmaceuticals to a “sell” rating in a research note on Tuesday, July 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Friday, May 3rd. SVB Leerink started coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. They set an “outperform” rating and a $5.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Lexicon Pharmaceuticals in a research note on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.67.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.